search
Back to results

Safety of an Inactivated Enterovirus Type 71 Vaccine in Healthy Adults

Primary Purpose

Infection; Viral, Enterovirus

Status
Completed
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
Inactivated Enterovirus Type 71 Vaccine
Placebo
Sponsored by
Sinovac Biotech Co., Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Infection; Viral, Enterovirus

Eligibility Criteria

18 Years - 49 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Healthy males and females, aged from 18 to 49 years old. Health is determined by medical history, physical examination, laboratory examination and clinical judgment of the investigator
  2. Provided legal identification for the sake of recruitment.
  3. Subjects are able to understand and sign informed consents.

Exclusion Criteria:

  1. Histroy of Hand-foot-mouth Disease
  2. Women of lactation, pregnancy or about to be pregnant in 60 days
  3. Subject that has allergic history of vaccine, or allergic to any ingredient of vaccine
  4. Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain
  5. Congenital malformations or developmental disorders, genetic defects, or severe malnutrition
  6. Epilepsy, seizures or convulsions history, or family history of mental illness
  7. Autoimmune disease or immunodeficiency, or parents, brothers and sisters have autoimmune diseases or immunodeficiency
  8. History of asthma, angioedema, diabetes or malignancy
  9. History of thyroidectomy or thyroid disease that required medication within the past 12 months
  10. Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws
  11. Asplenia, functional asplenia or any condition resulting in the absence or removal the spleen
  12. Acute illness or acute exacerbation of chronic disease within the past 7 days
  13. Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis)
  14. History of any blood products within 3 months
  15. Administration of any live attenuated vaccine within 28 days
  16. Administration of subunit or inactivated vaccines ,e.g., pneumococcal vaccine, or allergy treatment within 14 days
  17. Axillary temperature > 37.0 centigrade before vaccination
  18. Abnormal laboratory parameters before vaccination
  19. Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent

Sites / Locations

  • GuangXi Center for Diseases Control and Prevention

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Placebo Comparator

Placebo Comparator

Arm Label

Group 1: 200U EV71 vaccine

Group 2: 400U EV71 vaccine

Group 1: Placebo

Group 2: Placebo

Arm Description

12 adults received 3 doses of 200U EV71 vaccine 14 days apart

12 adults received 3 doses of 400U EV71 vaccine 14 days apart

6 adults received 3 doses of placebo 14 days apart

6 adults received 3 doses of placebo 14 days apart

Outcomes

Primary Outcome Measures

To evaluate the safety and tolerability of the inactivated Enterovirus Type 71 Vaccine in adults by different doses

Secondary Outcome Measures

Full Information

First Posted
January 7, 2011
Last Updated
March 13, 2013
Sponsor
Sinovac Biotech Co., Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT01273233
Brief Title
Safety of an Inactivated Enterovirus Type 71 Vaccine in Healthy Adults
Official Title
A Blinded, Randomized and Controlled Clinical Trial of An Inactivated Enterovirus Type 71 Vaccine in Healthy Adults
Study Type
Interventional

2. Study Status

Record Verification Date
March 2013
Overall Recruitment Status
Completed
Study Start Date
December 2010 (undefined)
Primary Completion Date
February 2011 (Actual)
Study Completion Date
February 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sinovac Biotech Co., Ltd

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
A blind, randomized and placebo-controlled clinical trial with Inactivated Enterovirus Type 71 Vaccines in healthy adults
Detailed Description
A total of 36 eligible subjects aged from 18 to 49 years will be enrolled in the study, they will be randomized to receive two different dosage of vaccine candidate or placebo to evaluate the safety of this vaccine in adults

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infection; Viral, Enterovirus

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
36 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group 1: 200U EV71 vaccine
Arm Type
Experimental
Arm Description
12 adults received 3 doses of 200U EV71 vaccine 14 days apart
Arm Title
Group 2: 400U EV71 vaccine
Arm Type
Experimental
Arm Description
12 adults received 3 doses of 400U EV71 vaccine 14 days apart
Arm Title
Group 1: Placebo
Arm Type
Placebo Comparator
Arm Description
6 adults received 3 doses of placebo 14 days apart
Arm Title
Group 2: Placebo
Arm Type
Placebo Comparator
Arm Description
6 adults received 3 doses of placebo 14 days apart
Intervention Type
Biological
Intervention Name(s)
Inactivated Enterovirus Type 71 Vaccine
Other Intervention Name(s)
EV71 Vaccine
Intervention Description
A Sinovac EV71 vaccine contains inactivated EV71 virus, aluminum hydroxide, sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate and injection water. The EV71 vaccine is supplied in one mono-dose vial containing 0.5 mL of viral suspension with EV71 virus antigen of 200U and 400U (Elisa unit)
Intervention Type
Other
Intervention Name(s)
Placebo
Other Intervention Name(s)
EV71 Vaccine
Intervention Description
Placebo is suspension with a little ivory precipitation, composition of which is aluminum hydroxide diluents.
Primary Outcome Measure Information:
Title
To evaluate the safety and tolerability of the inactivated Enterovirus Type 71 Vaccine in adults by different doses
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
49 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Healthy males and females, aged from 18 to 49 years old. Health is determined by medical history, physical examination, laboratory examination and clinical judgment of the investigator Provided legal identification for the sake of recruitment. Subjects are able to understand and sign informed consents. Exclusion Criteria: Histroy of Hand-foot-mouth Disease Women of lactation, pregnancy or about to be pregnant in 60 days Subject that has allergic history of vaccine, or allergic to any ingredient of vaccine Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory difficulty, angioedema, or abdominal pain Congenital malformations or developmental disorders, genetic defects, or severe malnutrition Epilepsy, seizures or convulsions history, or family history of mental illness Autoimmune disease or immunodeficiency, or parents, brothers and sisters have autoimmune diseases or immunodeficiency History of asthma, angioedema, diabetes or malignancy History of thyroidectomy or thyroid disease that required medication within the past 12 months Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws Asplenia, functional asplenia or any condition resulting in the absence or removal the spleen Acute illness or acute exacerbation of chronic disease within the past 7 days Any history of immunosuppressive medications or cytotoxic medications or inhaled corticosteroids within the past six months (with the exception of corticosteroid nasal spray for allergic rhinitis or topical corticosteroids for an acute uncomplicated dermatitis) History of any blood products within 3 months Administration of any live attenuated vaccine within 28 days Administration of subunit or inactivated vaccines ,e.g., pneumococcal vaccine, or allergy treatment within 14 days Axillary temperature > 37.0 centigrade before vaccination Abnormal laboratory parameters before vaccination Any medical, psychiatric, social condition, occupational reason or other responsibility that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a volunteer's ability to give informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yan-ping Li, MD
Organizational Affiliation
Guangxi Centers for Disease Control and Prevention
Official's Role
Principal Investigator
Facility Information:
Facility Name
GuangXi Center for Diseases Control and Prevention
City
Nanning
State/Province
Guangxi
Country
China

12. IPD Sharing Statement

Citations:
PubMed Identifier
22426327
Citation
Li YP, Liang ZL, Gao Q, Huang LR, Mao QY, Wen SQ, Liu Y, Yin WD, Li RC, Wang JZ. Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial. Vaccine. 2012 May 9;30(22):3295-303. doi: 10.1016/j.vaccine.2012.03.010. Epub 2012 Mar 15.
Results Reference
derived

Learn more about this trial

Safety of an Inactivated Enterovirus Type 71 Vaccine in Healthy Adults

We'll reach out to this number within 24 hrs